Cited by 435Alzheimer's disease research and treatmentsNF-κB Signaling PathwaysNeuroinflammation and Neurodegeneration Mechanisms

Increased NF-Κb Signalling Up-Regulates BACE1 Expression and its Therapeutic Potential in Alzheimer's Disease

Open access
Chen, Chia-Hsiung, Zhou, Weihui, Liu, Shengchun, Deng, Yu, Cai, Fang, Tone, Masahide, Tone, Yukiko, Tong, Yigang +1 more·2012·The International Journal of Neuropsychopharmacology

Abstract

Elevated levels of β-site APP cleaving enzyme 1 (BACE1) were found in the brain of some sporadic Alzheimer's disease (AD) patients; however, the underlying mechanism is unknown. BACE1 cleaves β-amyloid precursor protein (APP) to generate amyloid β protein (Aβ), a central component of neuritic plaques in AD brains. Nuclear factor-kappa B (NF-κB) signalling plays an important role in gene regulation and is implicated in inflammation, oxidative stress and apoptosis. In this report we found that both BACE1 and NF-κB p65 levels were significantly increased in the brains of AD patients. Two functional NF-κB-binding elements were identified in the human BACE1 promoter region. We found that NF-κB p65 expression resulted in increased BACE1 promoter activity and BACE1 transcription, while disruption of NF-κB p65 decreased BACE1 gene expression in p65 knockout (RelA-knockout) cells. In addition, NF-κB p65 expression leads to up-regulated β-secretase cleavage and Aβ production, while non-steroidal anti-inflammatory drugs (NSAIDs) inhibited BACE1 transcriptional activation induced by strong NF-κB activator tumour necrosis factor-alpha (TNF-α). Taken together, our results clearly demonstrate that NF-κB signalling facilitates BACE1 gene expression and APP processing, and increased BACE1 expression mediated by NF-κB signalling in the brain could be one of the novel molecular mechanisms underlying the development of AD in some sporadic cases. Furthermore, NSAIDs could block the inflammation-induced BACE1 transcription and Aβ production. Our study suggests that inhibition of NF-κB-mediated BACE1 expression may be a valuable drug target for AD therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1461145711000149

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Buggia-Prevot V, Sevalle J, Rossner S, Checler F (2008). NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42. Journal of Biological Chemistry 283, 10037-10047.

Cited by

Sorted by citations

Authors
Chen, C.-H., Zhou, W., Liu, S., Deng, Y., Cai, F., Tone, M., Tone, Y., Tong, Y., & Song, W.
Affiliations
  • University of British Columbia (CA)
  • University of Pennsylvania (US)
Corresponding author
Song, Weihong
Venue
The International Journal of Neuropsychopharmacology
Published
2011-02-18
Volume
15
Issue
01
Pages
77-90
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2158215064
Cited by
433
References
41
Citations by year
2026: 33 · 2025: 55 · 2024: 51 · 2023: 39 · 2022: 40 · 2021: 26 · 2020: 47 · 2019: 25 · 2018: 25 · 2017: 18 · 2016: 20 · 2015: 17 · 2014: 12 · 2013: 11 · 2012: 6
FWCI
7.85
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Michael Smith Health Research BC
  • Canada Research Chairs
  • Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, BACE1, NF-κB signaling, NF-κB p65, beta-secretase, amyloid-beta production, APP processing, transcriptional regulation, nonsteroidal anti-inflammatory drugs, TNF-α, inflammation, therapeutic target
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Brain, Humans, Promoter Regions, Genetic, Transcription, Genetic, Tumor Necrosis Factor-alpha, Signal Transduction, Up-Regulation, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Transcription Factor RelA, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review